循環腫瘍細胞の世界市場レポート 2025年

循環腫瘍細胞市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.8％で216億8,000万米ドルに成長します。予測期間の成長は、ポイントオブケアCTC検査、マイクロフルイディクスの採用、希少がん種への注力、CTCアッセイの標準化、CTCベースの臨床試験の拡大、経済成長、新興市場の成長に起因すると考えられます。予測期間における主な動向としては、CTC分離技術の革新、CTC研究に対する政府資金援助、CTC検出技術の進歩、がんモニタリングのためのリキッドバイオプシー、シングルセル解析との統合、人工知能（AI）との技術的融合などが挙げられます。

がんの罹患率の増加は、今後の循環腫瘍細胞市場の成長を促進すると予想されます。がんは、特定の体細胞の制御不能な増殖を特徴とする疾患であり、他の部位に転移する可能性があります。循環腫瘍細胞はがんの早期発見・診断に利用されるため、がん患者の増加に伴い循環腫瘍細胞市場の拡大に寄与しています。例えば、米国の任意団体である米国がん学会誌は、2023年1月に米国で新たに195万8310人のがん患者が発生し、60万9820人ががん関連で死亡すると予測しています。このように、がんの罹患率の増加が循環腫瘍細胞市場の成長に拍車をかけています。

臨床試験で循環腫瘍細胞分析の採用が増加していることも、市場成長の重要な促進要因になりそうです。新しい治療法の安全性と有効性を評価するために不可欠な臨床試験は、循環腫瘍細胞（CTC）分析の統合によって恩恵を受ける。この統合により、治療反応を評価する能力が強化され、早期発見とモニタリングが可能になり、特定の患者プロファイルに合わせて介入を調整し、全体として臨床エンドポイントの効率と検証が向上します。2023年5月現在、ClinicalTrials.govは452,604件の臨床試験が登録され、64,838件が積極的に参加者を求めていると報告しています。この臨床試験の急増は、2021年に登録された365,000試験から増加しており、研究における循環腫瘍細胞分析の採用が増加していることを裏付けています。その結果、臨床試験におけるCTC分析の統合の拡大は、循環腫瘍細胞市場を推進する主要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界循環腫瘍細胞 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の循環腫瘍細胞市場：成長率分析
• 世界の循環腫瘍細胞市場の実績：規模と成長, 2019-2024
• 世界の循環腫瘍細胞市場の予測：規模と成長, 2024-2029, 2034F
• 世界循環腫瘍細胞総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の循環腫瘍細胞市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• キットと試薬
• 採血管
• デバイスまたはシステム
• 世界の循環腫瘍細胞市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• CTCエンリッチメント
• CTC検出
• CTC分析
• 世界の循環腫瘍細胞市場標本別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血
• 骨髄
• その他の体液
• 世界の循環腫瘍細胞市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床または液体生検
• 調査
• 世界の循環腫瘍細胞市場、キットと試薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞濃縮キット
• 検出キット
• 核酸分離キット
• 世界の循環腫瘍細胞市場、採血管の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準採血管
• 特殊採血管
• 世界の循環腫瘍細胞市場、デバイスまたはシステムのタイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• マイクロ流体デバイス
• 自動細胞捕捉システム
• イメージングシステム

第7章 地域別・国別分析

• 世界の循環腫瘍細胞市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の循環腫瘍細胞市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 循環腫瘍細胞市場：競合情勢
• 循環腫瘍細胞市場：企業プロファイル
  • Precision Medicine Group LLC Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
  • BIOCEPT Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Creativ MicroTech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Fluxion Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ikonisys Inc.
• Qiagen N.V.
• ScreenCell SAS
• STEMCELL Technologies Inc.
• Sysmex Corporation
• Aviva Biosciences Corporation
• LungLife AI Inc.
• Miltenyi Biotec GmbH
• Menarini Silicon Biosystems S.p.A.
• Canopus Bioscience Ltd.
• IVDiagnostics Inc.
• BioFluidica Inc.
• Biolidics Limited
• Rarecells Diagnostics SAS
• LineaRx Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 循環腫瘍細胞市場2029：新たな機会を提供する国
• 循環腫瘍細胞市場2029：新たな機会を提供するセグメント
• 循環腫瘍細胞市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.

The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.

The circulating tumor cells market research report is one of a series of new reports from The Business Research Company that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The circulating tumor cells market size has grown rapidly in recent years. It will grow from $11.9 billion in 2024 to $13.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to cancer incidence and prevalence, clinical utility in cancer staging, emergence of liquid biopsy, patient demand for minimally invasive tests, regulatory support for liquid biopsies, focus on early cancer detection.

The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $21.68 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to point-of-care CTC testing, adoption of microfluidics, focus on rare cancer types, standardization of CTC assays, expansion of CTC-based clinical trials, economic and emerging market growth. Major trends in the forecast period include innovations in CTC isolation techniques, government funding for CTC research, advancements in CTC detection technologies, liquid biopsy for cancer monitoring, integration with single-cell analysis, technological convergence with artificial intelligence (AI).

The increasing incidence of cancer is expected to drive the growth of the circulating tumor cells market in the future. Cancer is a disease characterized by the uncontrolled growth of certain body cells, which can spread to other areas. Circulating tumor cells are utilized for the early detection and diagnosis of cancer, thereby contributing to the expansion of the circulating tumor cells market as cancer cases rise. For example, in January 2023, the American Cancer Society Journals, a US-based voluntary health organization, projected that 1,958,310 new cancer cases would be diagnosed in the United States, with 609,820 expected cancer-related deaths. Thus, the rising incidence of cancer is fueling the growth of the circulating tumor cells market.

The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.

Product innovations are a significant trend gaining traction in the circulating tumor cells market. Major companies in this sector are concentrating on developing innovative products to bolster their market position. For example, in June 2024, Bio-Rad Laboratories, Inc., a US-based medical laboratory, introduced the Celselect Slides 2.0. This product is designed to improve the capture of rare cells and circulating tumor cells (CTCs), thereby enhancing the accuracy and efficiency of cell analysis for both clinical and research applications.

Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.

In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).

Major companies operating in the circulating tumor cells market include Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd.

North America was the largest region in the circulating tumor cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Circulating Tumor Cells Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on circulating tumor cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for circulating tumor cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The circulating tumor cells market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Kits And Reagents; Blood Collection Tubes; Devices Or Systems
• 2) By Technology: CTC Enrichment; CTC Detection; CTC Analysis
• 3) By Specimen: Blood; Bone Marrow; Other Body Fluids
• 4) By Application: Clinical Or Liquid Biopsy; Research
• Subsegments:
• 1) By Kits And Reagents: Cell Enrichment Kits; Detection Kits; Nucleic Acid Isolation Kits
• 2) By Blood Collection Tubes: Standard Blood Collection Tubes; Specialized Blood Collection Tubes
• 3) By Devices Or Systems: Microfluidic Devices; Automated Cell Capture Systems; Imaging Systems
• Companies Mentioned: Precision Medicine Group LLC; Bio-Techne Corporation; BIOCEPT Inc.; Creativ MicroTech Inc.; Fluxion Biosciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Circulating Tumor Cells Market Characteristics

3. Circulating Tumor Cells Market Trends And Strategies

4. Circulating Tumor Cells Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Circulating Tumor Cells Growth Analysis And Strategic Analysis Framework

• 5.1. Global Circulating Tumor Cells PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Circulating Tumor Cells Market Growth Rate Analysis
• 5.4. Global Circulating Tumor Cells Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Circulating Tumor Cells Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Circulating Tumor Cells Total Addressable Market (TAM)

6. Circulating Tumor Cells Market Segmentation

• 6.1. Global Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kits And Reagents
• Blood Collection Tubes
• Devices Or Systems
• 6.2. Global Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CTC Enrichment
• CTC Detection
• CTC Analysis
• 6.3. Global Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood
• Bone Marrow
• Other Body Fluids
• 6.4. Global Circulating Tumor Cells Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Or Liquid Biopsy
• Research
• 6.5. Global Circulating Tumor Cells Market, Sub-Segmentation Of Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cell Enrichment Kits
• Detection Kits
• Nucleic Acid Isolation Kits
• 6.6. Global Circulating Tumor Cells Market, Sub-Segmentation Of Blood Collection Tubes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Blood Collection Tubes
• Specialized Blood Collection Tubes
• 6.7. Global Circulating Tumor Cells Market, Sub-Segmentation Of Devices Or Systems, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Microfluidic Devices
• Automated Cell Capture Systems
• Imaging Systems

7. Circulating Tumor Cells Market Regional And Country Analysis

• 7.1. Global Circulating Tumor Cells Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Circulating Tumor Cells Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Circulating Tumor Cells Market

• 8.1. Asia-Pacific Circulating Tumor Cells Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Circulating Tumor Cells Market

• 9.1. China Circulating Tumor Cells Market Overview
• 9.2. China Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Circulating Tumor Cells Market

• 10.1. India Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Circulating Tumor Cells Market

• 11.1. Japan Circulating Tumor Cells Market Overview
• 11.2. Japan Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Circulating Tumor Cells Market

• 12.1. Australia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Circulating Tumor Cells Market

• 13.1. Indonesia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Circulating Tumor Cells Market

• 14.1. South Korea Circulating Tumor Cells Market Overview
• 14.2. South Korea Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Circulating Tumor Cells Market

• 15.1. Western Europe Circulating Tumor Cells Market Overview
• 15.2. Western Europe Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Circulating Tumor Cells Market

• 16.1. UK Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Circulating Tumor Cells Market

• 17.1. Germany Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Circulating Tumor Cells Market

• 18.1. France Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Circulating Tumor Cells Market

• 19.1. Italy Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Circulating Tumor Cells Market

• 20.1. Spain Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Circulating Tumor Cells Market

• 21.1. Eastern Europe Circulating Tumor Cells Market Overview
• 21.2. Eastern Europe Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Circulating Tumor Cells Market

• 22.1. Russia Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Circulating Tumor Cells Market

• 23.1. North America Circulating Tumor Cells Market Overview
• 23.2. North America Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Circulating Tumor Cells Market

• 24.1. USA Circulating Tumor Cells Market Overview
• 24.2. USA Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Circulating Tumor Cells Market

• 25.1. Canada Circulating Tumor Cells Market Overview
• 25.2. Canada Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Circulating Tumor Cells Market

• 26.1. South America Circulating Tumor Cells Market Overview
• 26.2. South America Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Circulating Tumor Cells Market

• 27.1. Brazil Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Circulating Tumor Cells Market

• 28.1. Middle East Circulating Tumor Cells Market Overview
• 28.2. Middle East Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Circulating Tumor Cells Market

• 29.1. Africa Circulating Tumor Cells Market Overview
• 29.2. Africa Circulating Tumor Cells Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Circulating Tumor Cells Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Circulating Tumor Cells Market, Segmentation By Specimen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Circulating Tumor Cells Market Competitive Landscape And Company Profiles

• 30.1. Circulating Tumor Cells Market Competitive Landscape
• 30.2. Circulating Tumor Cells Market Company Profiles
  • 30.2.1. Precision Medicine Group LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. BIOCEPT Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Creativ MicroTech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fluxion Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Circulating Tumor Cells Market Other Major And Innovative Companies

• 31.1. Ikonisys Inc.
• 31.2. Qiagen N.V.
• 31.3. ScreenCell SAS
• 31.4. STEMCELL Technologies Inc.
• 31.5. Sysmex Corporation
• 31.6. Aviva Biosciences Corporation
• 31.7. LungLife AI Inc.
• 31.8. Miltenyi Biotec GmbH
• 31.9. Menarini Silicon Biosystems S.p.A.
• 31.10. Canopus Bioscience Ltd.
• 31.11. IVDiagnostics Inc.
• 31.12. BioFluidica Inc.
• 31.13. Biolidics Limited
• 31.14. Rarecells Diagnostics SAS
• 31.15. LineaRx Inc.

32. Global Circulating Tumor Cells Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Circulating Tumor Cells Market

34. Recent Developments In The Circulating Tumor Cells Market

35. Circulating Tumor Cells Market High Potential Countries, Segments and Strategies

• 35.1 Circulating Tumor Cells Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Circulating Tumor Cells Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Circulating Tumor Cells Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer